Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 26 opinions in the last 12 months.
Johnson & Johnson (JNJ) is viewed largely favorably among analysts despite ongoing challenges, notably the talcum powder litigation, which many believe could soon be resolved, leading to a potential rebound in stock performance. The company has a strong presence in the pharmaceutical and medical devices sectors following a recent spinoff, and it boasts a pristine balance sheet with a history of dividend increases. Analysts highlight the attractive valuation, with a price-to-earnings ratio in the low 14s, bolstered by a solid dividend yield around 3.3%. Social media buzz surrounding the company has surged, reflecting increased interest, and many experts suggest that now may be a good time to buy given its relatively low price and stable financials. The consensus is that, while the stock has faced some pressures, it presents a compelling opportunity for long-term investors willing to ride out current volatility.
After spinoff, now just pharma and medical technologies/devices. One of 2 AAA-rated US companies (the other is MSFT). Pristine balance sheet forever. Divvy increases for 62 consecutive years, all from free cashflow. Crazy-cheap valuation of 14-15x PE, partly due to ongoing talc litigation. Yield is 3.34%.
Recent press release was like none other. Company stated talc litigation based on fake science; if the other side won't settle, JNJ will litigate each and every case separately. He suspects this is a ploy to force a settlement. Expects it to be over by year's end.
Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N
In the last year, 9 stock analysts published opinions about JNJ-N. 3 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.
Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
9 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.
On 2025-06-06, Johnson & Johnson (JNJ-N) stock closed at a price of $155.03.
Has a triple-A balance sheet and many drugs in the pipeline. But it pays only a 3.55% dividend, below interest rates, and still suffers the legal overhang of its talcum powder allegedly caused ovarian cancer.